{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:34:26Z","timestamp":1792092866652,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002923","name":"CONICET","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-2017-0977"],"award-info":[{"award-number":["PICT-2017-0977"]}],"id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00262-021-03043-x","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T17:44:46Z","timestamp":1630431886000},"page":"979-987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype"],"prefix":"10.1007","volume":"71","author":[{"given":"Esteban Enrique","family":"Elias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Judith","family":"Sarapura Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikele","family":"Amondarain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Colado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Cordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimundo Fernando","family":"Bezares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Fernandez Grecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Rosario","family":"Custidiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C\u00e9sar","family":"S\u00e1nchez \u00c1valos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Garate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Borge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9680-0691","authenticated-orcid":false,"given":"Romina","family":"Gamberale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"issue":"4","key":"3043_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic Leukemia. N Engl J Med 374(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"22","key":"3043_CR2","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMc1805135","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Mobasher M, Kater AP (2018) Venetoclax-rituximab in chronic lymphocytic Leukemia. N Engl J Med 378(22):2143\u20132144. https:\/\/doi.org\/10.1056\/NEJMc1805135","journal-title":"N Engl J Med"},{"issue":"23","key":"3043_CR3","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Du K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380(23):2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1815281","journal-title":"N Engl J Med"},{"issue":"9","key":"3043_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C (2018) Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103(9):1511\u20131517. https:\/\/doi.org\/10.3324\/haematol.2018.193615","journal-title":"Haematologica"},{"issue":"10","key":"3043_CR5","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.3324\/haematol.2018.188680","volume":"103","author":"EE Elias","year":"2018","unstructured":"Elias EE, Almejun MB, Colado A, Cordini G, Vergara-Rubio M, Podaza E, Risnik D, Cabrejo M, Fernandez-Grecco H, Bezares RF, Custidiano MDR, Sanchez-Avalos JC, Vicente A, Garate GM, Borge M, Giordano M, Gamberale R (2018) Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies. Haematologica 103(10):e458\u2013e461. https:\/\/doi.org\/10.3324\/haematol.2018.188680","journal-title":"Haematologica"},{"issue":"25","key":"3043_CR6","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","volume":"127","author":"K Bojarczuk","year":"2016","unstructured":"Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, Efremov DG (2016) BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood 127(25):3192\u20133201","journal-title":"Blood"},{"issue":"7","key":"3043_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","volume":"128","author":"S Oppermann","year":"2016","unstructured":"Oppermann S, Ylanko J, Shi Y, Hariharan S, Oakes CC, Brauer PM, Zuniga-Pflucker JC, Leber B, Spaner DE, Andrews DW (2016) High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood 128(7):934\u2013947","journal-title":"Blood"},{"issue":"8","key":"3043_CR8","first-page":"e302","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, Kater AP, Eldering E (2015) Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica 100(8):e302-306","journal-title":"Haematologica"},{"issue":"6","key":"3043_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PPO.0000000000000408","volume":"25","author":"CE Ryan","year":"2019","unstructured":"Ryan CE, Davids MS (2019) BCL-2 Inhibitors present and future. Cancer J 25(6):401\u2013409. https:\/\/doi.org\/10.1097\/PPO.0000000000000408","journal-title":"Cancer J"},{"issue":"4","key":"3043_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00262-016-1946-y","volume":"66","author":"A Colado","year":"2017","unstructured":"Colado A, Almejun MB, Podaza E, Risnik D, Stanganelli C, Elias EE, Dos Santos P, Slavutsky I, Fernandez Grecco H, Cabrejo M, Bezares RF, Giordano M, Gamberale R, Borge M (2017) The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. Cancer Immunol Immunother 66(4):461\u2013473","journal-title":"Cancer Immunol Immunother"},{"issue":"11\u201312","key":"3043_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","volume":"17","author":"C Calissano","year":"2011","unstructured":"Calissano C, Damle RN, Marsilio S, Yan XJ, Yancopoulos S, Hayes G, Emson C, Murphy EJ, Hellerstein MK, Sison C, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Ivanovic I, Dozmorov IM, Roa S, Scharff MD, Li W, Chiorazzi N (2011) Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells. Mol Med 17(11\u201312):1374\u20131382","journal-title":"Mol Med"},{"key":"3043_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004326","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, Tam C, Forconi F, Chiodin G, Brown JR, Dubois J, Kater AP, Eldering E (2020) Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. https:\/\/doi.org\/10.1182\/blood.2019004326","journal-title":"Blood"},{"issue":"2","key":"3043_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","volume":"11","author":"P Lu","year":"2021","unstructured":"Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, Wu W, Niu N, Sukhanova M, Pei J, Baldwin DA, Nejati R, Wasik MA, Khan N, Tu Y, Gao J, Chen Y, Ma S, Larson RA, Wang YL (2021) Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J 11(2):39. https:\/\/doi.org\/10.1038\/s41408-021-00429-z","journal-title":"Blood Cancer J"},{"issue":"25","key":"3043_CR14","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","volume":"129","author":"MA Anderson","year":"2017","unstructured":"Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW (2017) Clinico-pathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 129(25):3362\u20133370","journal-title":"Blood"},{"issue":"7","key":"3043_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","volume":"42","author":"R He","year":"2018","unstructured":"He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, Tian S, Dao LN, Parikh SA, Shanafelt TD, Call TG, Ansell SM, Leis JF, Mai M, Hanson CA, Rech KL (2018) PD-1 Expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness. Am J Surg Pathol 42(7):843\u2013854. https:\/\/doi.org\/10.1097\/PAS.0000000000001077","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"3043_CR16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.2012.077537","volume":"98","author":"D Brusa","year":"2013","unstructured":"Brusa D, Serra S, Coscia M, Rossi D, D\u2019Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S (2013) The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 98(6):953\u2013963. https:\/\/doi.org\/10.3324\/haematol.2012.077537","journal-title":"Haematologica"},{"issue":"14","key":"3043_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","volume":"1","author":"KD Jayappa","year":"2017","unstructured":"Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ (2017) Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv 1(14):933\u2013946","journal-title":"Blood Adv"},{"issue":"22","key":"3043_CR18","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W (2019) Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095\u20132103. https:\/\/doi.org\/10.1056\/NEJMoa1900574","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03043-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T17:23:10Z","timestamp":1647278590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03043-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3043"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03043-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GC: Astrazeneca honoraria for advisory board. RFB: AbbVie and Astrazeneca honoraria for lectures and Microsules honoraria for advisory board. MRC: AbbVie honoraria for advisory board. GG: Janssen, Astrazaneca, Sanofi, Varifarma, Teva, Roche and Novartis honoraria for advisory board. MAP: Janssen, Astrazeneca, Raffo and AbbVie honoraria for lectures and Advisory boards. RG: Astrazeneca and AbbVie honoraria for lectures. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study has the approval of the Institutional Review Board from the Academia Nacional de Medicina, Buenos Aires, Argentina.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Samples used in this study were obtained after informed consent in accordance with the Declaration of Helsinki and with Institutional Review Board approval from the Academia Nacional de Medicina, Buenos Aires, Argentina.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}